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Abstract
Background: Lassa and Junı ´n viruses are the most prominent members of the Arenaviridae family of viruses that cause viral
hemorrhagic fever syndromes Lassa fever and Argentine hemorrhagic fever, respectively. At present, ribavirin is the only
antiviral drug indicated for use in treatment of these diseases, but because of its limited efficacy in advanced cases of
disease and its toxicity, safer and more effective antivirals are needed.
Methodology/Principal Findings: Here, we used a model of acute arenaviral infection in outbred guinea pigs based on
challenge with an adapted strain of Pichinde ´ virus (PICV) to further preclinical development of T-705 (Favipiravir), a
promising broad-spectrum inhibitor of RNA virus infections. The guinea pig-adapted passage 19 PICV was uniformly lethal
with an LD50 of ,5 plaque-forming units and disease was associated with fever, weight loss, thrombocytopenia,
coagulation defects, increases in serum aspartate aminotransferase (AST) concentrations, and pantropic viral infection.
Favipiravir (300 mg/kg/day, twice daily orally for 14 days) was highly effective, as all animals recovered fully from PICV-
induced disease even when therapy was initiated one week after virus challenge when animals were already significantly ill
with marked fevers and thrombocytopenia. Antiviral activity and reduced disease severity was evidenced by dramatic
reductions in peak serum virus titers and AST concentrations in favipiravir-treated animals. Moreover, a sharp decrease in
body temperature was observed shortly after the start of treatment. Oral ribavirin was also evaluated, and although
effective, the slower rate of recovery may be a sign of the drug’s known toxicity.
Conclusions/Significance: Our findings support further development of favipiravir for the treatment of severe arenaviral
infections. The optimization of the experimental favipiravir treatment regimen in the PICV guinea pig model will inform
critical future studies in the same species based on challenge with highly pathogenic arenaviruses such as Lassa and Junı ´n.
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Introduction
A limited number of phylogenetically distinct viruses that belong
to the Arenaviridae, Bunyaviridae, Filoviridae, and Flaviviridae families
can cause a severe hemorrhagic fever syndrome that often results
in death. Among the arenaviruses, two Old World (Lassa and
Lujo) and several New World (Junı ´n, Machupo, Guanarito, Sabia ´,
and Chapare) viruses are the etiologic agents of viral hemorrhagic
fever in endemic areas of Africa and South America, respectively
[1,2,3]. Estimates of the number of yearly Lassa virus infections
and associated deaths in West Africa range up to 2,000,000 and
10,000, respectively [4]. The highest disease burden in the New
World is associated with Junı ´n virus (JUNV) infection in the
Pampas agricultural regions of Argentina. Although an effective
vaccine has curtailed the number of cases of Argentine
hemorrhagic fever (AHF), cases continue to be reported annually
[5]. Immune plasma has been used with some success but has been
associated with a late neurological syndrome [6]. Ribavirin (1-b-D-
ribofuranosyl-1H-1, 2,4-triazole-3carboxamide) is the only li-
censed antiviral with reported activity against Lassa virus (LASV),
JUNV, and Machupo virus (MACV) [7,8,9], and could be used
off-label in the event of an emergency [10]. Although the adverse
effects in humans treated with ribavirin are generally considered
to be mild and reversible with termination of treatment [11,12,
13,14], teratogenicity and embryotoxicity are of concern [15,16].
In addition, intravenous ribavirin is not widely available and is
often very expensive [17].
Favipiravir (T-705; 6-flouro-3-hydroxy-2-pyrazinecarboxamide)
is a pyrazine derivative presently being developed clinically for the
treatment of influenza virus infections. Orally administered
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models of arenavirus, phlebovirus, flavivirus, and influenza virus
infections [18,19,20,21,22,23]. We were able to demonstrate a
limited protective antiviral effect when treating advanced Pichinde ´
virus (PICV) infection in hamsters [24]. In Vero cell culture
experiments, we have demonstrated micromolar range activity of
favipiravir against the JUNV vaccine strain, Candid 1 [19]. We
have now confirmed this activity with a pathogenic strain of
JUNV, as well as isolates of other South American hemorrhagic
fever viruses [25].
Although several groups have recently reported on the
development of mouse models of LASV and JUNV infection,
these systems are based on challenge of immunocompromised
animals [26,27]. Guinea pig infection models have been described
for LASV, JUNV and Guanarito virus (GTOV) [28,29,30,31],
and are the best-suited small animal models to further investigate
the activity of favipiravir. Due to the maximum containment
requirement and high costs associated with conducting studies
with highly pathogenic arenaviruses, the aim of the present work
was to evaluate favipiravir in the guinea pig PICV infection model
[32,33], as a means to optimize treatment conditions to assist in
the planning of future studies in biosafety level 4 (BSL-4)
containment. Our PICV stock derived from a single additional
passage of a previously described guinea pig-adapted virus [33]
was uniformly lethal in outbred guinea pigs, and we characterized
the natural history of disease to establish the model in our
laboratory for use in the evaluation of favipiravir.
Methods
Ethics statement
All animal procedures complied with USDA guidelines and
were conducted at the AAALAC-accredited Laboratory Animal
Research Center at Utah State University under protocol 1393,
approved by the Utah State University Institutional Animal Care
and Use Committee.
Animals
Outbred male Hartley strain guinea pigs weighing ,300–350 g
were obtained from Charles River (Wilmington, MA). Animals
were sorted prior to the start of all experiments so that the average
group weight was similar across all groups. For all experiments,
IPTT-300 electronic transponders were subcutaneously implanted
for identification and temperature measurement in conjunction
with the DAS 6002 scanner (BMDS, Seaford, DE).
Virus
Guineapig-adapted PICV,passage 18(p18),was providedbyDr.
Robert Tesh (World Reference Center for Emerging Viruses and
Arboviruses, University of Texas Medical Branch, Galveston, TX).
The p18 strain was derived from 2 additional passages of a p16
guinea pig spleen suspension of the CoAn 4763 Munchique strain
obtained from the U.S. Army Medical Research Institute of
Infectious Diseases (USAMRIID). A p19 spleen homogenate was
prepared from a single ill p18-infected guineapig euthanized on day
12 post-infection. The p19 stock (,4.8610
6 plaque-forming units
(PFU)/ml) was used for all challenge studies. Sequencing of viral
RNA isolated from the p19 stock was performed by SeqWright
DNA Technologies Services (Houston, TX) using standard
fluorescent dye-terminator DNA sequencing chemistry following
RT-PCR amplification. GenBank accession numbers for the p19 S
and L segments are JN378747 and JN7378748, respectively.
Test compounds
Favipiravir (T-705) was provided by the Toyama Chemical
Company, Ltd. (Tokyo, Japan). Ribavirin was supplied by ICN
Pharmaceuticals, Inc. (Costa Mesa, CA). Both were suspended in
GERBER NatureSelect 1st FOODS carrot food (ingredients:
carrots and water) for oral administration.
Favipiravir toxicity was assessed in guinea pigs following twice-
daily treatments for 10 days. Groups of five guinea pigs each were
dosed orally with 500, 250, 100 and 0 (placebo) mg/kg/day of
favipiravir. Treatments were administered using 1 ml tuberculin
syringes by placement of the doses in carrot food vehicle in the
back of the oral cavity. During the 10-day dosing period and for
seven days following, guinea pigs were monitored closely for signs
of toxicosis and weights and temperatures were recorded daily.
Seven days after the final dose was administered, animals were
euthanized by CO2 asphyxiation, whole blood and serum were
collected for hematology and blood chemistry analyses, and
necropsies and pathological examination were performed at the
Ross A. Smart Veterinary Diagnostic Laboratory (Logan, UT).
PICV titration and natural history studies
Virus titrations were performed to determine 50% and 90%
lethal doses (LD50 and LD90) of the p19 PICV stock. Groups of
three to four guinea pigs each were challenged by bilateral
intraperitoneal (i.p.) injections with log10 PICV quantities ranging
from 0.05 to 50,000 PFU prepared in minimal essential medium
(MEM). Body weight and temperature, and morbidity and
mortality were monitored for 28 days following infection. Clinical
signs of illness were weight loss, pyrexia, ruffling of fur, and
lethargy. In this and all other experiments, animals were
considered moribund and euthanized when they lost 20% of their
starting body weight or their body temperature dropped to 36uC
or less. For survival analysis, animals were counted as dead the day
after euthanasia. LD50 and LD90 values were determined by
regression analysis.
Based on the titration data, guinea pigs were infected with
500 PFU of PICV for the natural history study and the challenge
Author Summary
Several viruses in the Arenaviridae family cause severe life-
threatening hemorrhagic fever syndromes, which are
considered neglected tropical diseases in endemic areas
of Africa and South America. Ribavirin, the only licensed
antiviral indicated for use has limited efficacy when
treating advanced cases of disease and is associated with
toxicity. In the present study, we use a model of acute
arenaviral disease in guinea pigs based on infection with
an adapted strain of the Pichinde ´ arenavirus (PICV) to
further preclinical development of a promising broad-
spectrum antiviral drug candidate, favipiravir. Oral favipir-
avir was highly effective in the treatment of sick animals
with marked fevers, as all recovered fully from lethal PICV
infection even when therapy was initiated one week after
virus challenge. Antiviral activity and reduced disease
severity was evidenced by dramatic reductions in serum
virus loads and serum aspartate aminotransferase, an
enzyme released into the bloodstream following tissue
damage and a marker for severe arenaviral infections.
Moreover, a sharp decrease in fever was observed shortly
after the onset of treatment. Our findings support further
development of favipiravir for the treatment of severe
arenaviral infections, for which there are presently no safe
and effective therapies for treating advanced cases of
disease.
Favipiravir Therapy of Acute Arenavirus Infection
www.plosntds.org 2 October 2011 | Volume 5 | Issue 10 | e1342efficacy experiments. For the natural history study, PICV-
challenged guinea pigs were sacrificed daily (n=3/day), with the
exception of day 10 and 11 of infection, on which 4 and 2 guinea
pigs were euthanized, respectively, due to one of the day 11
animals having reached the 20% weight loss euthanasia criteria on
day 10. Whole blood (in both citrate- and EDTA-coated tubes;
Sarstedt Inc., Newton, NC), serum, livers, lungs, kidneys, spleens,
and brains were harvested. Whole spleens were weighed prior to
sectioning. Sections from each tissue were preserved in 10%
formalin and sent to the Ross A. Smart Veterinary Diagnostic
Laboratory (Logan, UT) for histologic analysis. The other sections
were stored at 280uC and virus titers determined as described
below. Whole blood was analyzed for coagulation and hemato-
logic parameters, and serum was analyzed for viremia and
comprehensive blood chemistry as described below.
Favipiravir efficacy studies
Two independent studies were performed to investigate the
efficacy of favipiravir in guinea pigs challenged with PICV. In the
first study, groups of 8 guinea pigs each were treated twice daily
with 100 and 30 mg/kg/day of favipiravir on days 4–7 of
infection. Due to continued deterioration of the animals despite
favipiravir treatment, the doses were increased to 300 and 90 mg/
kg/day, respectively, for the remainder of the treatment schedule
(days 8–17). For comparison, 8 guinea pigs each were treated twice
daily with 50 mg/kg/day of ribavirin or carrot food placebo on
days 4–17 after challenge. Body weight and temperature, and
morbidity and mortality were monitored for 29 days post-
challenge. Serum was collected by saphenous vein puncture from
all animals on day 11 of infection, with the exception of two
animals in the placebo group that had to be put down on day 10.
Serum was analyzed for viral burden, aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) as described below.
Serum was also collected from surviving animals at the conclusion
of the experiment (day 29) for virus titer analysis.
In the second study, groups of 8 guinea pigs each were treated
orally with 300 or 150 mg/kg/day favipiravir, or vehicle placebo,
divided into two daily doses for 14 days beginning on day 7 after
infection. In an attempt reduce the high viral loads encountered at
the start of treatment, the 150-mg/kg/day favipiravir group
received a loading dose of 300 mg/kg on the first day, with a shift
to the lower maintenance dose thereafter. This strategy is
commonly used in the clinic and has been employed for the
treatment of cases of Lassa fever and AHF [17,34]. A group of 7
guinea pigs received 50 mg/kg/day of ribavirin, with treatment
also starting on day 7 and given twice daily for 14 days. Guinea
pigs were monitored for signs of illness and weights and
temperatures were recorded as previously described. Serum was
collected on day 10 from all animals by saphenous vein puncture
and analyzed for viremia and AST concentration. Sera, spleens,
livers, lungs, kidneys, and brains were collected from surviving
animals at the end of the study (day 36) for virus titer analysis.
Serum and tissue virus titers
Virus titers were determined using an infectious cell culture
assay as previously described [19]. Briefly, tissues were homoge-
nized 1:10 w/v in MEM. Serum and homogenized tissue samples
were serially log10 diluted and plated in triplicate wells on Vero
cell monolayers (American Type Culture Collection, Manassas,
VA) in 96-well microtiter plates. Plates were incubated for 7 days
and viral cytopathic effect (CPE) was determined for calculation of
50% endpoints by the Reed-Muench method [35]. Assay
detection range was 1.8 to 8.5 log10 50% cell culture infectious
dose (CCID50)/ml of serum or 0.1 g of tissue.
Coagulation, hematology, and blood chemistry
Whole blood in citrate-coated tubes was analyzed for pro-
thrombin time (PT) and activated partial thromboplastin time
(aPTT) using the VetScan VSpro and PT/aPTT cartridges
(Abaxis Inc., Union City, CA). Due to a technical problem, PT
clot times were not detected in two of three animals on day 1.
For the characterization and efficacy studies, whole blood in
EDTA-coated tubes was analyzed for hematology using the
VetScan HMT (Abaxis Inc.). Hematology factors included white
blood cells (WBC), lymphocytes (Lym), monocytes (Mon),
granulocytes (Gra), red blood cells (RBC), mean corpuscular
volume (MCV), hematocrit (Hct), mean corpuscular hemoglobin
(MCH), mean corpuscular hemoglobin concentration (MCHC),
red cell distribution width (RDW), hemoglobin (Hb), platelets
(PLT), mean platelet volume (MPV), plateletcrit (PCT), and
platelet distribution width (PDW). For the favipiravir toxicity
study, hematology was performed using a HEMAVET HV 950
(Drew Scientific, Dallas, TX) and parameters evaluated were
equivalent to those above, except WBC were further broken down
to include neutrophils (Neu), eosinophils (Eos) and basophils (Bas).
Serum was analyzed for comprehensive blood chemistry or
individual analytes using the DRI-CHEM 4000 chemistry analyzer
(Heska, Loveland, CA). Blood analytes included AST, amylase
(AMY), alkaline phosphatase (ALP), ALT, blood urea nitrogen
(BUN), calcium (Ca), creatinine (CRE), gamma-glutamyl transfer-
ase (GGT), glucose (GLU), total protein (TP), total bilirubin (TBIL),
albumin (ALB), cholesterol (CHO), and inorganic phosphate (IP).
For the favipiravir toxicity study, blood chemistry analysis was
performed using the VetScan VS2 and comprehensive diagnostic
profile rotors (Abaxis Inc.). Similar analytes were profiled with the
exception of CHO and the addition of phosphate (PHOS), sodium
(Na
+), potassium (K
+), and globulin (GLOB).
Pharmacokinetic analysis of orally administered
favipiravir in guinea pigs by HPLC
Three guinea pigs were treated by placement of a 50 mg/kg dose
of favipiravir, suspended in carrot food vehicle, towards the back of
the oral cavity with a 1 ml syringe. Plasma was collected from each
animal at 15 min, 30 min, 1 h, 2 h, and 4 h by saphenous vein
puncture. Each sample was mixed with equal volume of 1:1
methanol:acetonitrile for deproteinization. Samples were centri-
fuged (10,0006g) for 10 min and supernatants transferred to new
tubes for evaporation. The contents were then resuspended in
HPLC buffer for analysis as previously described [24]. Favipiravir
plasma concentrations were extrapolated using a standard curve
from samples containing known amounts of favipiravir. Area under
the curve (AUC) analysis and half-life (t1/2) estimation were
performed using Prism (GraphPad Software, La Jolla, CA).
Statistical analysis
The Mantel-Cox log-rank test was performed to analyze the
survival data. Hematology, blood chemistry, virus titer, coagula-
tion, and spleen weight data were analyzed using one-way analysis
of variance (ANOVA) followed by Bonferroni multiple compar-
ison test. Correlation of PLT count with other platelet parameters
(PCT, MPV and PDW) were performed according to the Pearson
rank correlation method. All statistical evaluations were done
using Prism (GraphPad Software).
Results
Characterization of lethal PICV infection in guinea pigs
Because of the reported variability in lethality caused by PICV
infection of outbred guinea pigs [32,36,37,38,39], we sought to
Favipiravir Therapy of Acute Arenavirus Infection
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evaluation of favipiravir. We prepared a virus stock from a single
passage of the p18 guinea pig-adapted strain in Hartley guinea
pigs. The p19 PICV was derived from the spleen of clinically ill
guinea pig with an advanced infection on day 12 post-challenge.
The p19 stock was found to be highly virulent causing severe
disease in guinea pigs with 100% mortality at challenge doses
$500 PFU (Figure 1). The LD50 of the p19 stock was ,5 PFU
with an LD90 of ,200 PFU. Complete sequence analysis of the L
and S segments from the p19 virus stock revealed only a single
substitution in the consensus sequence compared to the previously
reported p18 sequences [39]. The substitution was present in the L
segment and was heterogeneous matching either the p18 or p2
sequences.
We next investigated the natural history of disease in guinea pigs
challenged with 500 PFU of the p19 virus. PICV-induced disease
in guinea pigs was marked by elevated temperatures beginning on
day 3 after infection, with weight loss and anorexia becoming
evident by day 6 (Figure 2A). Clot times for extrinsic (PT) and
intrinsic (aPTT) coagulation pathways were increased as the
infection progressed past day 7 (Figure 2B). Hematological analysis
revealed additional alterations affecting the coagulation system.
Marked thrombocytopenia was observed starting on day 5 post-
infection with dramatic decreases in platelet counts (PLT;
Figure 2C, Table S1) and plateletcrit (PCT; Table S1); the latter
measure being directly related to the total number of platelets.
Platelet distribution width (PDW), a marker for platelet activation
[40], concomitantly decreased and became increasingly variable as
the infection progressed and, due to low PLT, could not be
measured past day 7 (Table S1). On the other hand, mean platelet
volume (MPV), considered an indicator of platelet function [41],
did not significantly change over the course of the course of
the study and did not correlate with PLT (Table S1). PLT
concentration had a strong correlation with both PCT (r=1.0;
P=0.0001) and PDW (r=0.83; P=0.0015). The only other
notable hematologic findings observed were spikes in total WBC
and granulocytes (Gra) on day 7 of infection; however, both
parameters returned to the normal range the following day
(Table S1).
In addition to the depleted PLT and PCT levels, and the
prolonged coagulation times observed during the course of acute
PICV infection, we found blood in the stools of several ill animals
with advanced clinical disease signs (ruffling of fur and anorexia).
Evidence of hemorrhaging within individual tissues was not
observed upon pathological examination, suggesting that internal
bleeding into tissues was not contributing substantially to the
demise of the animals. Severe hemorrhagic manifestations are not
often seen in human arenaviral hemorrhagic fever cases [42,43].
Comprehensive blood chemistry analysis revealed a dramatic
increase in serum AST concentration starting on day 8 of PICV
infection (Figure 2D). In contrast, serum ALB decreased gradually
through the course of the infection (Table S2), which may reflect
alterations in vascular permeability or nutritional status. No other
significant changes in the blood chemistry parameters evaluated
were observed (Table S2).
Viremia and tissue virus titers were also assessed on a daily
basis. As shown in Figure 2E, PICV replication was observed in all
tissues examined. Onset of viremia occurred on day 5 post-
challenge and persisted through day 11. The spleen supported
vigorous replication as PICV could be detected as early as day 1,
and having the greatest viral loads throughout the acute infection
period, with titers of .10
8 CCID50/g. The liver, lungs, and
kidneys also had substantial viral burdens that crested on day 8
and persisted through the end of the study. Infectious virus was
detectable in the brain of several animals starting on day 7, but the
low titers may be attributable to blood-borne virus. This trend was
similarly observed in LASV-infected and PICV (p8 strain)-infected
strain 13 guinea pigs [28,32].
Consistent with the high viral loads measured in spleen tissue
homogenates, the spleens of PICV-infected guinea pigs were
Figure 1. Titration of PICV in outbred guinea pigs. Hartley guinea pigs were challenged i.p. with 50,000, 5000, 500, 50, 5, 0.5 (n=4/group), or
0.05 PFU (n=3) p19 PICV and survival plotted over a 28-day post-infection (p.i.) period. The data are combined from two separate experiments.
doi:10.1371/journal.pntd.0001342.g001
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infection compared to day 1 (Figure 2F). As described in previous
studies using lower passage strains of adapted PICV and inbred
strain 13 guinea pigs [32,44], we also found the liver and spleen to
be most affected histologically by p19 PICV infection (not shown),
although the degree of damage in these tissues was minor and less
than would have been expected based on viral titers (Figure 2E).
Few to moderate numbers of necrotic cells were observed in the
interstitium and periarteriolar sheaths of the spleen and acute
multifocal hepatic necrosis was observed as early as day 6 and
necrotic areas were more prominent in later days of infection (not
shown). Several guinea pigs exhibited hepatic lipidosis on days 10
and 11; however, this change is most likely due to the mobilization
of fat for energy as the sick animals greatly reduce food
consumption. All other tissues appeared normal upon histologic
examination. Our observations are consistent with those noted in
human Lassa fever, in which histopathologic findings are generally
not severe enough to account for death [45].
Favipiravir therapy of guinea pigs challenged with a
lethal dose of PICV
Having established a uniformly lethal guinea pig PICV infection
model and characterized the timing of disease progression, the
second objective was to evaluate the efficacy of oral favipiravir
using this model. Because of a small palatal ostium, oral gavage of
guinea pigs is very difficult and generally contraindicated. Thus,
we devised a method to treat the animals by suspending test drug
in a carrot food vehicle for administration as described in detail in
the methods section. Using this method of drug delivery, we were
able to confirm gastric absorption of favipiravir (AUC=44 mg/ml
h; t1/2=1.42 h) with peak plasma levels in the range of 40 mg/ml
(256 mM) within 15–30 min of treatment with a 50-mg/kg dose
(Figure S1).
To reach favipiravir concentrations well above the reported
50% effective concentration (EC50)o f,17 mM for arenavirus
inhibition in cell culture [19,46], we treated PICV-infected guinea
pigs with 100 or 30 mg/kg/day. This dose range has also been
previously shown to be effective in treating PICV infection in
hamsters by oral gavage [24]. Favipiravir, placebo, and ribavirin
(positive control) treatments were initiated 4 days after challenge
and dosed twice daily for 14 days (Figure 3A). Because we did not
observe any signs of toxicity following 10 days of treatment with a
favipiravir dose of 500 mg/kg/day (Table S3), we extended the
duration of treatment to facilitate complete clearance of the virus.
Unexpectedly, despite 4 days of therapy, guinea pigs treated with
favipiravir began to lose weight, became lethargic, and developed
high fevers similar to animals treated with placebo (Figure 3B, C).
In contrast, guinea pigs treated with ribavirin (50 mg/kg/day)
did not develop fever or show signs of illness. Consequently, we
decided to triple the dose of favipiravir for the remaining 10 days
of therapy starting on the morning of day 8 post-infection, as
no clinical signs of adverse effects, histopathology (not shown), or
changes in laboratory values were observed in toxicity studies
when guinea pigs were treated with up to 500 mg/kg/day
(Table S3).
The increase in the favipiravir dose resulted in a rapid reduction
in fever in the 300-mg/kg/day group (Figure 3C), with all animals
recovering completely (Figure 3A), as reflected by robust weight
gain at a rate greater than ribavirin (Figure 3B). The 90-mg/kg/
day dose of favipiravir provided a reduced, yet significant degree
of protection. Notably, the reduction in fever seen starting on day
9 for both the placebo and low-dose favipiravir groups is
principally due to decreasing temperatures in animals as they
become moribund (Figure 3C). Guinea pigs receiving ribavirin
therapy all survived the challenge, but recovered more slowly as
demonstrated by the shallower weight gain trend relative to the
high-dose favipiravir group. Serum AST and virus titers measured
on day 11 were significantly lower in all drug-treated groups
compared to the placebo, with a clear dose response evident with
the favipiravir-treated animals (Figure 3D, E). All surviving guinea
pigs had undetectable virus in the serum at the conclusion of the
experiment (not shown).
A second efficacy study was conducted wherein treatment was
initiated one week after virus challenge, to assess the ability of
favipiravir to treat more advanced PICV infection and disease in
Figure 2. Natural history of disease caused by PICV infection in guinea pigs. Animals were challenged with 500 PFU of p19 PICV, (A) daily
weights and temperatures were recorded, and groups of 3 were sacrificed on the indicated day p.i. for collection of blood and tissues for analysis of
(B) PT and aPTT clot times, (C) PLT counts, (D) serum AST levels, (E) infectious serum and tissue virus titers, and (F) splenomegaly during the course of
infection. Due to a technical problem, PT clot times were not detected in two of three animals on day 1. *P,0.05 compared to day 1 p.i. (day 3 p.i.
for PT).
doi:10.1371/journal.pntd.0001342.g002
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anorexia and sustained fever. Similar to the first experiment, we
were able to successfully treat lethal PICV challenge with a
300 mg/kg/day favipiravir regimen (Figure 4A), even when
delaying treatment until a time when animals presented with
considerable viral loads, splenomegaly, and were thrombocytope-
nic, febrile, and losing weight (Figure 2A, C, E, F). The
intermediate dose of 150 mg/kg/day of favipiravir, which
included a 300-mg/kg loading dose on the first day of treatment,
also provided a significant level of protection (Figure 4A). All
animals treated with ribavirin at 50 mg/kg/day survived the
challenge.
Figure 3. Treatment of lethal PICV infection with favipiravir starting 4 days after challenge. Guinea pigs (n=8/group) challenged with
500 PFU of p19 PICV were treated twice daily for 14 days with favipiravir, ribavirin, or placebo beginning on day 4 of infection (capped hashed line).
Animals receiving favipiravir were initially fed 100 and 30 mg/kg/d (days 4 to 7) before increasing the doses to 300 and 90 mg/kg/d, respectively,
starting on day 8 (indicated by arrow). (A) Survival, (B) body weights, and (C) temperatures were monitored for 29 days. Serum was collected on day
11 for analysis of (D) AST and (E) viremia, with the exception of two moribund animals from the placebo group that had to be sacrificed on day 10.
*P,0.05 compared to placebo-treated animals.
doi:10.1371/journal.pntd.0001342.g003
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PICV challenge (Figure 4B). The high-dose favipiravir group
decreased in body weight until day 9, at which point the animals
began to steadily recover throughout the remainder of the
experiment. Guinea pigs in the intermediate-dose favipiravir
treatment group that succumbed to illness steadily decreased in
body weight, while surviving counterparts began to recover as
early as day 11. Guinea pigs in the ribavirin treatment group
maintained fairly steady weights through day 21, when they began
to gradually gain weight through the rest of the observation
period. In both studies, slower rate of weight gain compared to the
high-dose favipiravir group was observed. Animals in the placebo
group sharply decreased in body weight prior to succumbing to the
infection.
Figure 4. Favipiravir treatment of advanced PICV infection in guinea pigs. Guinea pigs (n=7–8/group) challenged with 500 PFU of p19
PICV were treated with the indicated dosages of favipiravir, ribavirin, or placebo beginning on day 7 of infection. The 150-mg/kg/d group received a
loading dose of 300 mg/kg/d on the first day of treatment. Drugs were administered twice daily for 14 days (capped hashed line) and (A) survival, (B)
body weights, and (C) temperatures were monitored for 36 days. Serum was collected on day 10 for analysis of (D) AST and (E) viremia. *P,0.05
compared to placebo-treated animals.
doi:10.1371/journal.pntd.0001342.g004
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.40uC by day 6 of PICV infection (Figure 4C). Similar to the
initial efficacy study, fever was almost immediately reduced
following the onset of therapy with 300 mg/kg/day of favipiravir.
As before, it is important to note that prior to succumbing to the
infection, animals in the intermediate-dose favipiravir and placebo
groups dropped in temperature as they approached the terminal
stage of the disease.
Serum AST, reflective of the extent of tissue damage, was
significantly lower in all drug-treated groups compared to the
placebo when measured on day 10 post PICV challenge
(Figure 4D). Serum virus titers were also significantly lower in all
treatment groups, with average titers of 6.4 log10 CCID50/ml in
the placebo, and 4.3, 5.1, and 4.8 log10 CCID50/ml in the high-
and intermediate-dose favipiravir, and ribavirin groups, respec-
tively (Figure 4E). The treated guinea pigs that survived the 36 day
observation period were all found to be devoid of systemic and
tissue virus titers (not shown).
Discussion
Because there are presently no other small animal model
options based on challenge of immune competent animals with
highly pathogenic viral hemorrhagic fever-causing arenaviruses,
future studies evaluating favipiravir as an antiviral therapy for the
treatment of severe arenaviral infections will likely first be done in
guinea pig JUNV, GTOV, or LASV infection models that require
BSL-4 maximum biocontainment facilities [47]. To this end, we
sought to establish a guinea pig PICV infection model similar to
those previously described [32,33]. PICV infection in guinea pigs
has proven to be useful for the study of acute arenaviral disease
[37,38,39,44] and for preclinical efficacy evaluations [48,49], as
the virus can be handled safely in BSL-2 containment. There have
been mixed reports on the lethality of guinea pig-adapted PICV in
the readily available Hartley outbred guinea pig strain
[32,36,37,38,39]. In addition to other factors, the variation in
the stringency of the criteria used to define the terminal endpoints
likely contributed to the reported variability. We found that our
PICV stock prepared from the spleen of a clinically ill Hartley
guinea pig sacrificed on day 12 of infection was uniformly lethal
when inoculated at i.p. at doses of 500 PFU or more, but the
genetic make-up of the virus did not vary substantially from
previously reported sequences. Because most of the previous
studies with PICV in guinea pigs that investigated pathogenesis,
pathophysiology, virology, and clinical chemistry have used inbred
animals that varied in age, gender, and/or infectious dose of
PICV, we first characterized the p19 PICV infection in male 350 g
outbred guinea pigs. The results provided a detailed picture into
the evolution of the clinical disease and pathophysiology specific to
the present model, facilitating the evaluation of favipiravir with the
goal of demonstrating anti-arenavirus activity in guinea pigs and
optimizing the dosing method, level, frequency, and duration of
treatment to inform future BSL-4 studies.
With an understanding of the natural history of disease in our
guinea pig p19 PICV infection model, we assessed the anti-
arenavirus activity of orally administered favipiravir. Although
previously we were able to show limited efficacy with favipiravir in
treating advanced PICV disease in a hamster model [24], here we
were able to demonstrate complete protection from lethal disease
in guinea pigs when treatment was initiated well after the onset of
fever and the beginning of weight loss. Notably, PICV-infected
hamsters do not develop fever, and weight loss is not apparent
until the day prior to death [50]. To this end, the insidious
progression of the human disease is better reflected in guinea pigs,
including the development of fever, a hallmark of the clinical
arenaviral hemorrhagic fever diseases. Importantly, favipiravir
significantly reduced viremia and systemic AST concentrations,
which are prognostic indicators for severe disease and lethality in
Lassa fever patients [51]. The efficacy studies conducted provide
the foundation for more advanced evaluations with favipiravir
employing guinea pig infection models based on challenge with
authentic arenaviral hemorrhagic fever viruses, such as the JUNV-
guinea pig model actively being used to study AHF [30].
Although we were able to effectively treat PICV-infected guinea
pigs with favipiravir, the dosage required was higher than expected
based on previous studies in hamsters [19,24]. A dose of 300 mg/
kg/day was needed to achieve 100% survival in guinea pigs
challenged with PICV, whereas a 100-mg/kg/day therapeutic
regimen afforded the same level of protection when initiated as
late as day 5 following infection in hamsters [24]. To put these
findings into perspective, the dosage presently being used for
clinical evaluation of favipiravir for influenza treatment in humans
is 40 mg/kg/day on the first day, with a reduction to 27 mg/kg/
day for an additional 4 days. Nevertheless, the equivalent 300-mg/
kg/day guinea pig dosage based on body surface area translation
[52] would be 65 mg/kg/day. For hamsters, the 100-mg/kg/day
dosage would be 14 mg/kg/day.
The higher dose requirement of favipiravir in the guinea pig
model is not likely due to differences in the virus stocks used, as our
analysis of the An 4763 strain used to infect hamsters and the p19
guinea-pig adapted strain used in the present study were equally
sensitive to the inhibitory effects of favipiravir in cell culture (M.
Mendenhall, unpublished data). The evidence to date suggests that
favipiravir acts as a purine nucleoside analog targeting the viral
RNA-dependent RNA polymerase [25,53]. We hypothesize that
the difference in effective dosage of favipiravir is most likely due to
a less efficient conversion of the parent compound, T-705, to its
active triphosphate form (T-705RTP) in guinea pigs, and/or a
more rapid systemic elimination. However, we cannot rule out the
possibility of better absorption and more favorable biodistribution
of favipiravir in 0.4% carboxymethyl cellulose vehicle when given
by oral gavage, as previously described for hamsters [19,24].
Notwithstanding, our present findings, coupled with having
recently demonstrated favipiravir activity in cell culture against
JUNV, GTOV, and MACV [25], have us positioned to investigate
activity against arenaviruses that are the etiologic agents of
Argentine and Venezuelan hemorrhagic fevers in humans, in
existing guinea pig infection models [30,31].
Supporting Information
Figure S1 PK analysis of favipiravir in guinea pigs
dosed by oral cavity placement. Favipiravir (50 mg/kg) was
prepared in carrot food vehicle and administered by placement of
the dose towards the back of the palate with a tuberculin syringe.
Plasma was collected at 0.25, 0.5, 1, 2 or 4 h after treatment from
3 guinea pigs treated on 2 separate days. Samples were processed
and analyzed by HPLC for separation and measurement of
favipiravir as described in the methods section.
(TIFF)
Table S1 Hematological values during the course of
PICV infection in guinea pigs
a.
a Groups of guinea pigs
(n=3) were sacrificed daily through the course of PICV infection
and whole blood was collected for hematologic analysis.
b The
day-10 group (n=4) included a moribund guinea pig from the
day-11 group.
c The day-11 group consisted of 2 guinea pigs.
d
Total WBC and Gra were significantly increased on day 7
compared to day 1 (P,0.05).
e PLT and PCT were significantly
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www.plosntds.org 8 October 2011 | Volume 5 | Issue 10 | e1342lower on days 5–10 and 6–11, respectively, compared to day 1
(P,0.05).
f PDW could not be accurately calculated due to
depleted platelet counts on days 8–11. WBC, white blood cells;
Lym, lymphocytes; Mon, monocytes; Gra, granulocytes; RBC, red
blood cells; MCV, mean corpuscular volume; HCT, hematocrit;
MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular
hemoglogin concentration; RDW, red cell distribution width; Hb,
hemoglobin; PLT, platelets; MPV, mean platelet volume; PCT,
plateletcrit; and PDW, platelet distribution width.
(DOC)
Table S2 Blood chemistry profile during PICV infection
in guinea pigs
a.
a Groups of guinea pigs (n=3) were sacrificed
daily through the course of PICV infection and whole blood was
collected for blood chemistry analysis.
b The day-10 group (n=4)
included a moribund guinea pig from the day-11 group.
c The
day-11 group consisted of 2 guinea pigs.
d Serum AST was
significantly higher on day 10 compared to day 1 (P,0.05).
e Serum ALB was significantly lower on days 9 and 10 compared
to day 1 (P,0.05).
f Values were below the limit of detection
(50 mg/dL) in all three guinea pigs. AST, aspartate aminotrans-
ferase; AMY, amylase; ALP, alkaline phosphatase; ALT, alanine
aminotransferase; BUN, blood urea nitrogen; ALB, albumin;
TBIL, total bilirubin; Ca, calcium; CRE, creatinine; GGT,
gamma-glutamyl transferase; GLU, glucose; TP, total protein;
TBIL, total bilirubin;. ALB, Albumin; CHO, cholesterol; IP,
inorganic phosphate.
(DOC)
Table S3 Hematology and blood chemistry analysis of
guinea pigs treated for 10 days with favipiravir
a.
a Guinea
pigs (n=5/group) treated orally twice daily for ten days with the
indicated doses of favipiravir and sacrificed 7 days after the final
dose was administered. Whole blood and sera were analyzed for
hematology and blood chemistry. WBC, white blood cells; Neu,
neutrophils; Lym, lymphocytes; Mon, monocytes; Eos, eosinophils;
Bas, basophils; RBC, red blood cells; Hb, hemoglobin; HCT,
hematocrit; MCV, mean corpuscular volume; MCH, mean
corpuscular hemoglobin; MCHC, mean corpuscular hemoglogin
concentration; RDW, red cell distribution width; PLT, platelets;
MPV, mean platelet volume; ALB, albumin; ALP, alkaline
phosphatase; ALT, alanine aminotransferase; AMY, amylase;
TBIL, total bilirubin; BUN, blood urea nitrogen; Ca, calcium,
PHOS, phosphate; CRE, creatinine; GLU, glucose; Na
+, sodium;
K
+, potassium; TP, total protein; GLOB, globulin.
(DOC)
Author Contributions
Conceived and designed the experiments: BBG JOH YF. Performed the
experiments: MM AR BBG. Analyzed the data: BBG MM DFS JOH RS
YF. Contributed reagents/materials/analysis tools: YF DFS RS. Wrote the
paper: MM BBG.
References
1. Charrel RN, de Lamballerie X (2003) Arenaviruses other than Lassa virus.
Antiviral Research 57: 89–100.
2. Delgado S, Erickson BR, Agudo R, Blair PJ, Vallejo E, et al. (2008) Chapare
virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case
in Bolivia. PLoS Pathog 4: e1000047.
3. Briese T, Paweska JT, McMullan LK, Hutchison SK, Street C, et al. (2009)
Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-
associated arenavirus from southern Africa. PLoS Pathog 5: e1000455.
4. Fichet-Calvet E, Rogers DJ (2009) Risk maps of Lassa fever in West Africa.
PLoS Negl Trop Dis 3: e388.
5. Enria DA, Briggiler AM, Sanchez Z (2008) Treatment of Argentine
hemorrhagic fever. Antiviral Res 78: 132–139.
6. Maiztegui JI, Fernandez NJ, de Damilano AJ (1979) Efficacy of immune plasma
in treatment of Argentine haemorrhagic fever and association between treatment
and a late neurological syndrome. Lancet 2: 1216–1217.
7. Enria DA, Briggiler AM, Levis S, Vallejos D, Maiztegui JI, et al. (1987)
Tolerance and antiviral effect of ribavirin in patients with Argentine
hemorrhagic fever. Antiviral Res 7: 353–359.
8. Kilgore PE, Ksiazek TG, Rollin PE, Mills JN, Villagra MR, et al. (1997)
Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clinical
Infectious Diseases 24: 718–722.
9. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, et al. (1986) Lassa
fever. Effective therapy with ribavirin. New England Journal of Medicine 314:
20–26.
10. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, et al. (2002)
Hemorrhagic fever viruses as biological weapons: medical and public health
management. Jama 287: 2391–2405.
11. Bodenheimer HC, Jr., Lindsay KL, Davis GL, Lewis JH, Thung SN, et al.
(1997) Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a
multicenter trial. Hepatology 26: 473–477.
12. Chapman LE, Mertz GJ, Peters CJ, Jolson HM, Khan AS, et al. (1999)
Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance
during 1 year of open-label experience. Ribavirin Study Group. Antivir Ther 4:
211–219.
13. Fisher-Hoch SP, Gborie S, Parker L, Huggins J (1992) Unexpected adverse
reactions during a clinical trial in rural west Africa. Antiviral Res 19: 139–147.
14. Russmann S, Grattagliano I, Portincasa P, Palmieri VO, Palasciano G (2006)
Ribavirin-induced anemia: mechanisms, risk factors and related targets for
future research. Curr Med Chem 13: 3351–3357.
15. Kochhar DM, Penner JD, Knudsen TB (1980) Embryotoxic, teratogenic, and
metabolic effects of ribavirin in mice. Toxicol Appl Pharmacol 52: 99–112.
16. Ferm VH, Willhite C, Kilham L (1978) Teratogenic effects of ribavirin on
hamster and rat embryos. Teratology 17: 93–101.
17. Bausch DG, Hadi CM, Khan SH, Lertora JJ (2010) Review of the literature and
proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for
Lassa fever. Clin Infect Dis 51: 1435–1441.
18. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, et al. (2002) In vitro
and in vivo activities of anti-influenza virus compound T-705. Antimicrob
Agents Chemother 46: 977–981.
19. Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, et al. (2007) In
vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
Antimicrob Agents Chemother 51: 3168–3176.
20. Morrey JD, Taro BS, Siddharthan V, Wang H, Smee DF, et al. (2008) Efficacy
of orally administered T-705 pyrazine analog on lethal West Nile virus infection
in rodents. Antiviral research 80: 377–379.
21. Julander JG, Shafer K, Smee DF, Morrey JD, Furuta Y (2009) Activity of T-705
in a hamster model of yellow fever virus infection in comparison with that of a
chemically related compound, T-1106. Antimicrob Agents Chemother 53:
202–209.
22. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, et al. (2010) T-705
(favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad
Sci U S A 107: 882–887.
23. Sleeman K, Mishin VP, Deyde VM, Furuta Y, Klimov AI, et al. (2010) In Vitro
antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009
A(H1N1) viruses. Antimicrob Agents Chemother 54: 2517–2524.
24. Gowen BB, Smee DF, Wong MH, Hall JO, Jung KH, et al. (2008) Treatment of
late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and
reduced toxicity suggests an alternative to ribavirin. PLoS One 3: e3725.
25. Mendenhall M, Russell A, Juelich T, Messina EL, Smee DF, et al. (2010) T-705
(Favipiravir) Inhibition of Arenavirus Replication in Cell Culture. Antimicrob
Agents Chemother: In press.
26. Flatz L, Rieger T, Merkler D, Bergthaler A, Regen T, et al. (2010) T cell-
dependence of Lassa fever pathogenesis. PLoS Pathog 6: e1000836.
27. Kolokoltsova OA, Yun NE, Poussard AL, Smith JK, Smith JN, et al. (2010)
Mice lacking interferon {alpha}/{beta} and {gamma} receptors are susceptible
to Junin virus infection. J Virol.
28. Jahrling PB, Smith S, Hesse RA, Rhoderick JB (1982) Pathogenesis of Lassa
virus infection in guinea pigs. Infect Immun 37: 771–778.
29. Oubina JR, Carballal G, Videla CM, Cossio PM (1984) The guinea pig model
for Argentine hemorrhagic fever. Am J Trop Med Hyg 33: 1251–1257.
30. Yun NE, Linde NS, Dziuba N, Zacks MA, Smith JN, et al. (2008) Pathogenesis
of XJ and Romero strains of Junin virus in two strains of guinea pigs. Am J Trop
Med Hyg 79: 275–282.
31. Hall WC, Geisbert TW, Huggins JW, Jahrling PB (1996) Experimental infection
of guinea pigs with Venezuelan hemorrhagic fever virus (Guanarito): a model of
human disease. Am J Trop Med Hyg 55: 81–88.
32. Jahrling PB, Hesse RA, Rhoderick JB, Elwell MA, Moe JB (1981) Pathogenesis
of a pichinde virus strain adapted to produce lethal infections in guinea pigs.
Infection and Immunity 32: 872–880.
33. Aronson JF, Herzog NK, Jerrells TR (1994) Pathological and virological features
of arenavirus disease in guinea pigs. Comparison of two Pichinde virus strains.
American Journal of Pathology 145: 228–235.
Favipiravir Therapy of Acute Arenavirus Infection
www.plosntds.org 9 October 2011 | Volume 5 | Issue 10 | e134234. Enria DA, Maiztegui JI (1994) Antiviral treatment of Argentine hemorrhagic
fever. Antiviral Research 23: 23–31.
35. Reed LJ, Muench H (1938) A simple method of estimating fifty percent
endpoints. American Journal of Hygiene 27: 493–497.
36. Zhang L, Marriott K, Aronson JF (1999) Sequence analysis of the small RNA
segment of guinea pig-passaged Pichinde virus variants. Am J Trop Med Hyg
61: 220–225.
37. Zhang L, Marriott KA, Harnish DG, Aronson JF (2001) Reassortant analysis of
guinea pig virulence of pichinde virus variants. Virology 290: 30–38.
38. Scott EP, Aronson JF (2008) Cytokine patterns in a comparative model of
arenavirus haemorrhagic fever in guinea pigs. J Gen Virol 89: 2569–2579.
39. Lan S, McLay Schelde L, Wang J, Kumar N, Ly H, et al. (2009) Development of
infectious clones for virulent and avirulent pichinde viruses: a model virus to
study arenavirus-induced hemorrhagic fevers. J Virol 83: 6357–6362.
40. Vagdatli E, Gounari E, Lazaridou E, Katsibourlia E, Tsikopoulou F, et al. (2010)
Platelet distribution width: a simple, practical and specific marker of activation of
coagulation. Hippokratia 14: 28–32.
41. Choudhury A, Chung I, Blann AD, Lip GY (2007) Platelet surface CD62P and
CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of
platelet function in atrial fibrillation: a comparison of ‘‘healthy control subjects’’
and ‘‘disease control subjects’’ in sinus rhythm. J Am Coll Cardiol 49:
1957–1964.
42. Geisbert TW, Jahrling PB (2004) Exotic emerging viral diseases: progress and
challenges. Nat Med 10: S110–121.
43. Kunz S (2009) The role of the vascular endothelium in arenavirus haemorrhagic
fevers. Thromb Haemost 102: 1024–1029.
44. Connolly BM, Jenson AB, Peters CJ, Geyer SJ, Barth JF, et al. (1993)
Pathogenesis of Pichinde virus infection in strain 13 guinea pigs: an
immunocytochemical, virologic, and clinical chemistry study. American Journal
of Tropical Medicine and Hygiene 49: 10–24.
45. Walker DH, McCormick JB, Johnson KM, Webb PA, Komba-Kono G, et al.
(1982) Pathologic and virologic study of fatal Lassa fever in man. American
Journal of Pathology 107: 349–356.
46. Gowen BB, Wong MH, Jung KH, Smee DF, Morrey JD, et al. (2010) Efficacy of
favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease
models. Antiviral Res 86: 121–127.
47. Gowen BB, Holbrook MR (2008) Animal models of highly pathogenic RNA
viral infections: hemorrhagic fever viruses. Antiviral Res 78: 79–90.
48. Lucia HL, Coppenhaver DH, Baron S (1989) Arenavirus infection in the guinea
pig model: antiviral therapy with recombinant interferon-alpha, the immuno-
modulator CL246,738 and ribavirin. Antiviral Research 12: 279–292.
49. Soares MM, King SW, Thorpe PE (2008) Targeting inside-out phosphatidyl-
serine as a therapeutic strategy for viral diseases. Nat Med 14: 1357–1362.
50. Gowen BB, Julander JG, London NR, Wong MH, Larson D, et al. (2010)
Assessing changes in vascular permeability in a hamster model of viral
hemorrhagic fever. Virol J 7: 240.
51. Johnson KM, McCormick JB, Webb PA, Smith ES, Elliott LH, et al. (1987)
Clinical virology of Lassa fever in hospitalized patients. J Infect Dis 155:
456–464.
52. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to
human studies revisited. FASEB J 22: 659–661.
53. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, et al. (2005)
Mechanism of action of T-705 against influenza virus. Antimicrob Agents
Chemother 49: 981–986.
Favipiravir Therapy of Acute Arenavirus Infection
www.plosntds.org 10 October 2011 | Volume 5 | Issue 10 | e1342